Market Cap (In USD)
6.41 Million
Revenue (In USD)
-
Net Income (In USD)
-1.37 Million
Avg. Volume
2276.00
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.021-0.46
- PE
- -
- EPS
- -
- Beta Value
- -1.339
- ISIN
- US00848A1034
- CUSIP
- 00848A103
- CIK
- 1603345
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Martin Schroeder
- Employee Count
- -
- Website
- https://www.agentixcorp.com
- Ipo Date
- 2015-08-21
- Details
- Agentix Corp., a clinical development stage company, focuses on the development and commercialization of therapeutics to treat metabolic diseases. Its product pipeline includes AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, which has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver diseases. The company was formerly known as FairWind Energy, Inc. and changed its name to Agentix Corp. in June 2019. Agentix Corp. was incorporated in 2013 and is based in Dana Point, California.
More Stocks
-
300876
-
VCU
-
FEDERALBNKThe Federal Bank Limited
FEDERALBNK
-
CINEVISTACinevista Limited
CINEVISTA
-
MEDANTAGlobal Health Limited
MEDANTA
-
BIR
-
0HQ7The Buckle, Inc.
0HQ7
-
JUSTDIALJust Dial Limited
JUSTDIAL